Delayed graft function is a complication that occurs after kidney transplantation when the newly transplanted organ does not begin working immediately, requiring patients to continue dialysis treatment while the kidney gradually recovers its function.

When a Transplanted Kidney Needs Time to Wake Up

Kidney transplantation represents a life-changing opportunity for people with end-stage kidney disease, offering freedom from dialysis and improved quality of life. However, not all transplanted kidneys start working right away. Some need additional time to recover from the journey from donor to recipient, a situation doctors call delayed graft function, or DGF. This condition affects a significant number of transplant patients and requires careful management in the days and weeks following surgery.^[1]

The primary goal of managing delayed graft function is to support the patient while the kidney gradually begins to function on its own. This involves continuing dialysis treatments temporarily, closely monitoring kidney function through blood tests and urine output measurements, and carefully adjusting medications to protect the new organ. Treatment also focuses on preventing complications that could threaten the transplant’s long-term success, such as rejection episodes or infections. The approach varies depending on how long the delay lasts, the patient’s overall health, and specific characteristics of both the donor kidney and the recipient.^[3]

Understanding delayed graft function is important because its occurrence and duration can influence both short-term recovery and long-term transplant outcomes. Medical teams must balance providing adequate support during the recovery period with preventing potential complications. Standard treatments already approved by transplant societies form the foundation of care, while researchers continue investigating new therapies in clinical trials that might reduce the risk of delayed graft function or improve outcomes for patients who experience it.^[2]

How Delayed Graft Function Is Recognized and Understood

The diagnosis of delayed graft function centers on a practical definition used by most transplant centers: the need for at least one dialysis session within the first week after kidney transplantation. While this definition offers a straightforward way for hospitals and registries to track outcomes, doctors recognize it has limitations. Sometimes patients might need dialysis for reasons unrelated to the kidney’s function, such as high potassium levels or excess fluid that accumulated before the surgery.^[2]

Medical teams also monitor other signs that suggest the kidney is taking time to recover. These include measuring creatinine levels—a waste product that healthy kidneys normally filter from the blood—and tracking how much urine the patient produces. Doctors look for gradual improvement in these measurements over days to weeks as the kidney “wakes up” following transplant. Some kidneys may produce small amounts of urine but not enough to eliminate the need for temporary dialysis support.^[4]

The reported frequency of delayed graft function has increased over the years, despite improvements in preventing rejection and better surgical techniques. In the United States, rates rose from about 15% in the late 1980s to approximately 21-23% in more recent years. This increase coincides with changes in organ donation practices, including greater use of kidneys from older donors, donors who experienced cardiac death before organ recovery, and kidneys that may have experienced some injury before donation. These expanded donor criteria help more patients receive transplants but carry higher risks of delayed function.^[2]

Delayed graft function occurs more commonly with deceased donor kidneys compared to living donor kidneys. About one in three kidney transplants from deceased donors experience this complication, with even higher rates when the donation occurs after circulatory death. Living donor transplants have much lower rates of delayed function because these kidneys typically spend less time outside the body and come from healthier donors.^[4]

Standard Treatment Approaches for Supporting Recovery

The cornerstone of managing delayed graft function involves providing supportive care while the kidney gradually recovers its filtering ability. This supportive approach includes continuing dialysis treatments—the same blood-cleaning procedure patients received before transplant—until the new kidney can adequately remove waste products and excess fluid on its own. The frequency of dialysis sessions depends on the patient’s individual needs, waste product levels in the blood, and fluid status.^[4]

Careful medication management represents another critical component of standard care. Transplant teams must balance maintaining adequate immunosuppression to prevent rejection while avoiding medications that might further stress the recovering kidney. Some centers delay starting or reduce doses of calcineurin inhibitors—powerful immunosuppressive drugs like tacrolimus or cyclosporine—because these medications can reduce blood flow to the kidney. However, the evidence supporting this strategy and its impact on long-term outcomes remains unclear.^[6]

Blood pressure and fluid balance require close attention during the recovery period. Maintaining stable blood pressure and adequate hydration helps ensure the kidney receives sufficient blood flow to heal and begin functioning. Doctors avoid medications that could harm the recovering kidney, particularly drugs known to be nephrotoxic—meaning they can damage kidney tissue. This includes being cautious with certain antibiotics, pain medications, and other substances that healthy kidneys tolerate but injured ones may not.^[3]

Hospital length of stay typically extends for patients with delayed graft function compared to those whose kidneys work immediately. The median stay is often around three days for uncomplicated transplants, but can be significantly longer when delayed function occurs. Some transplant centers have developed specialized outpatient management programs that allow carefully selected patients to return home and receive dialysis at their regular dialysis center while attending frequent clinic appointments for monitoring. This approach requires excellent coordination between the transplant team and dialysis facility.^[8]

Monitoring protocols during delayed graft function include regular blood tests to measure kidney function markers like creatinine and blood urea nitrogen, electrolyte levels to ensure safe balance of sodium and potassium, and urine output when present. Doctors also watch for signs of rejection, which can be difficult to distinguish from delayed function. If the kidney fails to show improvement within expected timeframes—typically within two to three weeks—or if function worsens unexpectedly, doctors may recommend a kidney biopsy. This procedure involves removing a tiny piece of kidney tissue with a needle to examine under a microscope, helping identify whether rejection or other problems are preventing recovery.^[9]

Understanding Why Delayed Graft Function Occurs

The underlying cause of delayed graft function involves a complex injury process called ischemia-reperfusion injury. This occurs in two phases. First, during the time the kidney spends outside the body—called ischemia time—the organ receives no blood flow and therefore no oxygen, causing cells to become stressed and damaged. This period includes both “warm ischemia” when the kidney is at body temperature during surgical removal and “cold ischemia” when it is preserved in ice or special cooling machines during transport. Longer ischemia times increase the risk of delayed function.^[3]

The second phase occurs when blood flow returns to the kidney during transplant surgery—called reperfusion. Paradoxically, restoring blood flow triggers additional injury through inflammatory processes and production of harmful molecules. Blood vessel cells and filtering cells in the kidney respond to reperfusion by activating immune pathways that cause swelling and further damage. This combination of ischemia followed by reperfusion injury results in acute tubular necrosis—damage to the tiny tubes inside the kidney that concentrate urine and regulate fluid balance.^[2]

Multiple factors related to the donor kidney influence delayed graft function risk. Older donor age increases risk because aging kidneys have less reserve capacity to recover from injury. Kidneys from donors who required medications to maintain blood pressure or who had high creatinine levels before donation also face higher risk. Kidneys donated after circulatory death experience a period of warm ischemia that living donor kidneys avoid, substantially increasing delayed function rates. The overall health of the donor, including conditions like high blood pressure or diabetes, also matters.^[5]

Recipient factors also contribute to the likelihood of experiencing delayed graft function. Male recipients have slightly higher rates than female recipients. Higher body weight and longer time spent on dialysis before transplantation increase risk. The recipient’s immune system and inflammatory state at the time of transplant may influence how severely the kidney responds to ischemia-reperfusion injury. Proper management of blood pressure and fluid status during surgery and the immediate postoperative period can help minimize additional stress on the recovering kidney.^[5]

How Duration of Delayed Function Affects Transplant Outcomes

Research has shown that not all cases of delayed graft function carry the same implications for long-term transplant success. The duration of delayed function—how many days the kidney needs dialysis support before recovering—matters significantly. Studies have found that most kidneys recover function within 28 days, with 95% resolving by this point. Delayed function lasting less than 14 days appears to have minimal impact on long-term graft survival in many studies.^[5]

However, when delayed function extends beyond 28 days, the outlook becomes more concerning. Analysis of large transplant center data showed that prolonged delayed function lasting more than four weeks was associated with reduced death-censored graft survival—meaning kidneys were more likely to fail even when patient death was not the cause. Delayed function lasting 14 to 27 days falls in an intermediate risk category, with outcomes better than very prolonged delays but not as favorable as immediate function or very brief delays.^[5]

The mechanisms explaining why prolonged delayed function leads to worse long-term outcomes remain under investigation. One theory involves maladaptive repair—the idea that severe or prolonged injury causes kidneys to heal in ways that promote scarring rather than restoration of normal function. This scarring, called interstitial fibrosis, gradually reduces the kidney’s working tissue over time. Additionally, mitochondria—the energy-producing structures inside cells—may sustain lasting damage that impairs kidney function recovery. Delayed function has also been associated with higher rates of acute rejection episodes, which independently damage transplant kidneys.^[3]

Research estimating the lifetime health burden of delayed graft function has found substantial impacts. At nearly 14 years of follow-up, patients with delayed function had lower rates of functioning grafts (32% versus 52%), higher rates of return to dialysis (19% versus 10%), and higher mortality (50% versus 38%) compared to patients without delayed function. A typical 53-year-old patient with delayed function was projected to lose approximately 3 quality-adjusted life-years over their lifetime compared to a similar patient without this complication.^[13]

Promising Therapies Under Investigation in Clinical Trials

Given the significant impact of delayed graft function on transplant recipients, researchers have tested numerous interventions aimed at preventing or reducing its severity. Clinical trials have explored various strategies targeting different points in the transplantation process, from donor organ preservation to recipient treatment before and after surgery. While many tested therapies have shown promise in early studies, most have not yet demonstrated clear benefits in large-scale trials that change standard practice.^[6]

One area of investigation involves donor treatment before organ recovery. Early studies suggested that giving the donor dopamine—a medication that affects blood flow and kidney function—might reduce recipient dialysis needs after transplant. Dopamine can increase blood flow to the kidneys and has other effects that theoretically protect against ischemia-reperfusion injury. However, while initial research showed some promise in reducing delayed function rates, larger follow-up studies failed to demonstrate improvement in five-year graft survival, tempering enthusiasm for this approach.^[6]

Kidney preservation methods represent another focus of clinical research. Hypothermic machine perfusion—a technique where the kidney is connected to a machine that circulates cold preservation fluid through its blood vessels during storage—has been compared to traditional cold storage in ice. Studies have shown that machine perfusion can decrease rates of delayed graft function compared to static cold storage. However, the effect on long-term allograft survival remains uncertain, as extended follow-up data are still being collected. Despite this uncertainty, many transplant centers have adopted machine perfusion, particularly for kidneys at higher risk of delayed function.^[6]

Recipient treatments given around the time of surgery have also been explored in clinical trials. One small, single-center study investigated giving rabbit anti-thymocyte globulin—a powerful immunosuppressive medication—intravenously before blood flow was restored to the transplanted kidney. This open-label trial suggested reduced delayed function rates, but no larger, blinded studies have been conducted to confirm these findings. The theoretical benefit involves reducing the immune system’s inflammatory response when blood flow returns to the kidney.^[6]

A more recent Phase 3 clinical trial tested C1 esterase inhibitor, a medication that blocks part of the complement system—a component of the immune system involved in inflammation and tissue injury. The trial was a randomized, double-blind, placebo-controlled study assessing whether this drug could prevent delayed graft function when given to deceased donor kidney transplant recipients. While the study evaluated safety and effectiveness and followed patients for three years to assess long-term outcomes, the intervention showed minimal or no difference in delayed function rates compared to placebo, with no eventual effect on allograft function or survival.^[6]

Some clinical trials have explored whether modifying immunosuppression strategies immediately after transplant might reduce delayed graft function. Approaches include delaying the introduction of calcineurin inhibitors—drugs that can reduce kidney blood flow—or using minimal doses initially. The hypothesis is that avoiding these medications when the kidney is most vulnerable might allow better recovery. However, evidence supporting these strategies and demonstrating that they improve long-term outcomes remains limited. Transplant teams must balance any potential benefit against the risk of acute rejection that could occur with inadequate immunosuppression.^[6]

Most published intervention studies for delayed graft function have been disappointing in that they have shown minimal or no difference in rates with treatment, or no eventual effect on allograft function or survival. This pattern suggests that the biological processes underlying ischemia-reperfusion injury and delayed graft function are complex and difficult to prevent with single interventions. Future success may require coordinated efforts to protect the kidney at multiple stages of the transplantation process, from donor management through organ preservation and into the recipient’s early postoperative period.^[6]

Most Common Treatment Methods

• Supportive Care with Dialysis
  • Continuation of dialysis treatments temporarily until the transplanted kidney begins functioning adequately on its own
  • Frequency adjusted based on individual patient needs, blood waste product levels, and fluid balance
  • May be provided in hospital or through outpatient programs at regular dialysis centers with close transplant team coordination
• Blood Pressure and Fluid Management
  • Careful attention to maintaining stable blood pressure to ensure adequate blood flow to the recovering kidney
  • Medications to control blood pressure and regulate fluid levels
  • Avoidance of nephrotoxic drugs that could further damage the healing kidney tissue
• Immunosuppression Management
  • Balancing adequate immunosuppression to prevent rejection while protecting the recovering kidney
  • Some centers delay starting or reduce doses of calcineurin inhibitors to minimize kidney stress
  • Close monitoring for signs of rejection that can be difficult to distinguish from delayed function
• Kidney Function Monitoring
  • Regular blood tests measuring creatinine, blood urea nitrogen, and electrolyte levels
  • Tracking urine output when present as a sign of recovering function
  • Kidney biopsy if function fails to improve within expected timeframes or worsens unexpectedly
• Organ Preservation Techniques
  • Hypothermic machine perfusion during kidney storage has shown ability to decrease delayed graft function rates compared to traditional cold storage
  • Particularly used for kidneys at higher risk of delayed function
  • Involves circulating cold preservation fluid through kidney blood vessels during transport